rc 3095 has been researched along with trelstar in 1 studies
| Studies (rc 3095) | Trials (rc 3095) | Recent Studies (post-2010) (rc 3095) | Studies (trelstar) | Trials (trelstar) | Recent Studies (post-2010) (trelstar) |
|---|---|---|---|---|---|
| 108 | 2 | 26 | 1,998 | 483 | 490 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Groot, K; Milovanovic, SR; Radulovic, S; Schally, AV | 1 |
1 other study(ies) available for rc 3095 and trelstar
| Article | Year |
|---|---|
Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
Topics: Amino Acid Sequence; Animals; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bombesin; Cell Division; Gonadotropin-Releasing Hormone; Hormones; Humans; Insulin-Like Growth Factor I; Kinetics; Male; Mice; Mice, Nude; Molecular Sequence Data; Organ Size; Peptide Fragments; Prostate-Specific Antigen; Prostatic Neoplasms; Somatostatin; Transplantation, Heterologous; Triptorelin Pamoate | 1992 |